JP6771023B2 - Ｋ−ｒａｓ調節物質 - Google Patents

Ｋ−ｒａｓ調節物質 Download PDF

Info

Publication number
JP6771023B2
JP6771023B2 JP2018510695A JP2018510695A JP6771023B2 JP 6771023 B2 JP6771023 B2 JP 6771023B2 JP 2018510695 A JP2018510695 A JP 2018510695A JP 2018510695 A JP2018510695 A JP 2018510695A JP 6771023 B2 JP6771023 B2 JP 6771023B2
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
independently
nhc
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018510695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519357A (ja
JP2018519357A5 (enExample
Inventor
マコーミック，フランク
レンスロー，アダム・アール
ターナー，デイビッド
ギージン，シュテファン
メイシャッグ，アナ・イー
チェルトフ，オレーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2018519357A publication Critical patent/JP2018519357A/ja
Publication of JP2018519357A5 publication Critical patent/JP2018519357A5/ja
Application granted granted Critical
Publication of JP6771023B2 publication Critical patent/JP6771023B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
JP2018510695A 2015-05-06 2016-05-06 Ｋ−ｒａｓ調節物質 Expired - Fee Related JP6771023B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562157915P 2015-05-06 2015-05-06
US62/157,915 2015-05-06
US201562158356P 2015-05-07 2015-05-07
US62/158,356 2015-05-07
PCT/US2016/031344 WO2016179558A1 (en) 2015-05-06 2016-05-06 K-ras modulators

Publications (3)

Publication Number Publication Date
JP2018519357A JP2018519357A (ja) 2018-07-19
JP2018519357A5 JP2018519357A5 (enExample) 2019-06-13
JP6771023B2 true JP6771023B2 (ja) 2020-10-21

Family

ID=57218009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510695A Expired - Fee Related JP6771023B2 (ja) 2015-05-06 2016-05-06 Ｋ−ｒａｓ調節物質

Country Status (17)

Country Link
US (2) US10857140B2 (enExample)
EP (1) EP3291813A4 (enExample)
JP (1) JP6771023B2 (enExample)
KR (1) KR20180017013A (enExample)
CN (1) CN107847495A (enExample)
AU (1) AU2016258192B2 (enExample)
BR (1) BR112017023821A2 (enExample)
CA (1) CA2983927A1 (enExample)
CL (2) CL2017002786A1 (enExample)
EA (1) EA201792443A1 (enExample)
EC (1) ECSP17073743A (enExample)
HK (2) HK1251972A1 (enExample)
IL (1) IL255417A (enExample)
MA (1) MA42061A (enExample)
MX (1) MX2017014163A (enExample)
PH (1) PH12017501999A1 (enExample)
WO (1) WO2016179558A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379563B (zh) * 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
KR20180017013A (ko) 2015-05-06 2018-02-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 K-Ras 조절제
AU2017266911B2 (en) 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
CN110785414A (zh) 2017-04-20 2020-02-11 加利福尼亚大学董事会 K-Ras调节剂
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
HUE061599T2 (hu) 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok
TW202012396A (zh) * 2018-04-18 2020-04-01 美商德洛斯股份有限公司 具乙烯磺醯胺部分之k-ras調節劑
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
AU2019340436B2 (en) 2018-09-10 2025-04-17 Mirati Therapeutics, Inc. Combination therapies
CA3112129A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3946629A4 (en) * 2019-03-26 2023-04-05 University Of Massachusetts THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4034123A4 (en) 2019-09-24 2023-11-01 Mirati Therapeutics, Inc. COMBINATION THERAPIES
CN110981943B (zh) * 2019-12-02 2021-08-03 清华大学 多肽及其在制备药物中的用途和药物
CN119462626A (zh) 2019-12-20 2025-02-18 米拉蒂治疗股份有限公司 Sos1抑制剂
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
IL297650A (en) * 2020-04-27 2022-12-01 Verastem Inc Methods of treating abnormal cell growth
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
TW202214253A (zh) 2020-06-18 2022-04-16 美商銳新醫藥公司 延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
BR112023004569A2 (pt) 2020-09-11 2023-04-04 Mirati Therapeutics Inc Formas cristalinas de um inibidor de kras g12c
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
US11999753B2 (en) 2020-12-16 2024-06-04 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
EP4330228A4 (en) * 2021-04-26 2025-03-26 The Regents of the University of California G-ALPHA-S INHIBITORS AND USES THEREOF
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024155770A2 (en) * 2023-01-18 2024-07-25 Molecular Axiom, Llc Compositions for modulating kras expression and uses thereof
IL322247A (en) 2023-01-26 2025-09-01 Arvinas Operations Inc Cerebellon-based KRAS-disrupting proteins and related uses
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN121263417A (zh) 2023-06-30 2026-01-02 金橘生物科技公司 取代的稠合三环胺化合物及其作为ras抑制剂的用途
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131527A1 (de) 1981-08-08 1983-02-24 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPS61227567A (ja) 1985-04-01 1986-10-09 Eisai Co Ltd １，４−ジヒドロピリジン誘導体
DK626889A (da) 1988-12-16 1990-06-17 Roussel Uclaf Indanderivater, deres fremstilling samt laegemidler med indhold deraf
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
WO1996006078A1 (en) 1994-08-24 1996-02-29 Pfizer Pharmaceuticals Inc. N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists
US5475109A (en) * 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
US5631251A (en) 1995-06-07 1997-05-20 Merck & Co., Inc. 5-cyclopropyl-1,4 benzodiazepine-2-ones
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
MXPA01012322A (es) 1999-06-04 2002-07-22 Astrazeneca Ab Inhibidores de metaloproteinasas.
GEP20053476B (en) 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
WO2003004474A1 (en) 2001-07-06 2003-01-16 Syngenta Participations Ag Pesticidally active aminoacetonitriles
KR20050051691A (ko) * 2002-10-11 2005-06-01 아스트라제네카 아베 1,4-이치환 피페리딘 유도체 및 11-베타ｈｓｄ1억제제로서의 이들의 용도
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
EP1683797A1 (en) 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
UA83101C2 (en) 2003-12-15 2008-06-10 Алмирал Аг 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
ATE443701T1 (de) 2004-01-16 2009-10-15 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
CA2640807A1 (en) 2006-02-17 2007-08-23 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as 5ht2/d3 modulators
WO2007109154A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009015237A1 (en) 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
NZ593135A (en) 2008-12-19 2013-04-26 Novartis Ag Isoxazoline derivatives and their use as pesticide
TWI671297B (zh) 2009-05-27 2019-09-11 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
CN104379563B (zh) * 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
EP2698367A1 (en) 2012-08-14 2014-02-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benzimidazoles for the treatment of cancer
WO2014093230A2 (en) 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US9227978B2 (en) * 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
AU2014239542A1 (en) 2013-03-15 2015-10-01 Araxes Pharma Llc Covalent inhibitors of KRas G12C
US9776979B2 (en) 2013-09-26 2017-10-03 Sanford-Burnham Medical Research Institute EBI2 modulators
AU2016244017B2 (en) * 2015-04-03 2020-07-23 Nant Holdings Ip, Llc Compositions and methods of targeting mutant K-ras
KR20180017013A (ko) 2015-05-06 2018-02-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 K-Ras 조절제
SG11201808799SA (en) 2016-04-15 2018-11-29 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
CN110785414A (zh) 2017-04-20 2020-02-11 加利福尼亚大学董事会 K-Ras调节剂

Also Published As

Publication number Publication date
EP3291813A4 (en) 2019-01-02
AU2016258192A1 (en) 2017-11-16
HK1251972A1 (zh) 2019-05-10
US20180289683A1 (en) 2018-10-11
IL255417A (en) 2018-01-31
EP3291813A1 (en) 2018-03-14
WO2016179558A8 (en) 2017-11-16
WO2016179558A1 (en) 2016-11-10
MX2017014163A (es) 2018-08-15
MA42061A (fr) 2021-03-31
CN107847495A (zh) 2018-03-27
JP2018519357A (ja) 2018-07-19
US10857140B2 (en) 2020-12-08
PH12017501999A1 (en) 2018-04-02
CL2018003316A1 (es) 2019-03-15
HK1251485A1 (zh) 2019-02-01
AU2016258192B2 (en) 2021-07-29
KR20180017013A (ko) 2018-02-20
CA2983927A1 (en) 2016-11-10
US11541044B2 (en) 2023-01-03
CL2017002786A1 (es) 2018-06-22
EA201792443A1 (ru) 2018-10-31
BR112017023821A2 (pt) 2018-07-31
US20210196695A1 (en) 2021-07-01
ECSP17073743A (es) 2018-03-31

Similar Documents

Publication Publication Date Title
JP6771023B2 (ja) Ｋ−ｒａｓ調節物質
US11358940B2 (en) K-Ras modulators
US20170368173A1 (en) Cancer treatment combinations
US11840523B2 (en) IRE1α inhibitors and uses thereof
CN115916966A (zh) Strad结合剂及其用途
US20230052528A1 (en) Taspase1 inhibitors and uses thereof
EP3576728A1 (en) Compositions and methods for inhibiting reticulon 4
US11884649B2 (en) IRE1α inhibitors and uses thereof
US20230135758A1 (en) Elongation factor 1-alpha inhibitors and uses thereof
US10512630B2 (en) Compositions and methods for treating cancer
WO2015006615A1 (en) Anticancer agents
WO2019213620A1 (en) Epha4 cyclic peptide antagonists and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200928

R150 Certificate of patent or registration of utility model

Ref document number: 6771023

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees